EPO Biomarkers
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts
by the stimulating the bone marrow to manufacture red blood cells. There are five
different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin
zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered
subcutaneously as an alternative to iron supplements. Erythropoietin used in human
beings is also known as recombinant human erythropoietin (rHuEPO). Commercially
available rHuEPO has the same 165 amino acid sequence as available in naturally
occurring hormone but the level of glycosylation in rHuEPO depends on the testing
method used. Growing global incidence of renal diseases and cancers is expected to
create a marked increase in use of EPO biomarkers.
EPO Biomarkers Market: Drivers & Restraints
The prime drivers for the market include growing incidence of cancers and renal diseases.
Changes in lifestyle and improper eating habits contribute to pancreatic and endocrine
cancers, which often lead to severe anaemia, where external erythropoietin infusion is
required. Other drivers for the EPO biomarker market is technological advancement in
devising proprietary testing methods apart from tried and tested ones.
Restraints for the market include lack of availability of skilled labour and sufficient quality
controlled testing laboratories in most countries in less developed regions. Insufficient
R&D in identification of biomarkers due to adoption of cost cutting measures in European
regions is expected to restrain proper quantitative assessment of drugs and their
therapeutic efficacy in blood.
Report
Description
Report Description
This could also hamper progress of ongoing clinical trials and proper stratification of
patients.
Request free sample Report: http://www.futuremarketinsights.com/reports/sample/repgb-1382
EPO Biomarkers Market: Segmentation
EPO Biomarkers is classified on the basis of biomarker, indication, testing method and
end user type:
Based on biomarker type, the global EPO Biomarkers is segmented into the following:
• Recombinant human erythropoietin
• Erythropoietin alfa
• Erythropoietin beta
• Erythropoietin zeta
• Erythropoietin theta
• Darbepoietin alfa
Based on indication, the global EPO Biomarkers is segmented into following:
• End stage renal disorder
Report
Description
Report Description
• Cancers
• Rheumatoid arthritis
• AIDS
• Others
Based on end users, the global EPO Biomarkers is segmented into the following:
• Diagnostic centers
• Hospitals
• Ambulatory care and surgical centers
EPO Biomarkers Market: Overview
EPO biomarker market is account to rise in value during the forecast period. Due to
expansion in the product segment of EPO biomarkers the market share will be rising with
a promising rate, also with the increase in demand for diagnosis and treatment of widely
spread chronic disease the EPO market is expected to grow with a promising CAGR during
the forecast period. Biologic drug industry is investing on R&D and the key players are
focusing on increasing their production capacity for EPO biomarkers.
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1382
Report
Description
Report Description
EPO Biomarkers Market: Region-wise Outlook
Considering all potential geographic regions, EPO biomarkers market is segmented into
seven key regions: North America, Latin America, Eastern Europe, Western Europe,
Japan, Asia Pacific and Middle East & Africa. North America is been dominating in the
EPO biomarkers due to rise in acceptance for bio-similar weakly followed by Western and
Eastern Europe, Asia Pacific has a dominating presence in EPO biomarker market and
most of the key players are locally producing the EPO biomarkers, that is enhancing their
market share and product reach. There is a
good opportunity for Japan in EPO
biomarker market. The emerging regions in Asia Pacific, Middle East and Africa holds
promising future for rise in EPO biomarker market, due to increase in awareness towards
the chronic disease and increase in population simultaneously.
EPO Biomarkers Market: Key Players
Shandong Kexing Bioproducts Co., Ltd., Amgen Inc., Ranbaxy Laboratories Ltd, Johnson &
Johnson, Roche Holding AG, Sigma-Aldrich, Thermo Fisher Scientific, Hospira Inc., Biocon,
Teva Pharmaceutical Industries Ltd.,
Browse full report: http://www.futuremarketinsights.com/reports/epo-biomarkersmarket
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact: Mr. Sudip Saha
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705